Literature DB >> 11149419

Role of stimulatory guanine nucleotide binding protein (GSalpha) in proliferation of PC-3M prostate cancer cells.

J Chien1, G V Shah.   

Abstract

Previous studies have shown that calcitonin-like immunoreactive substances are secreted by primary prostate cells. Furthermore, exogenously added calcitonin stimulates proliferation of androgen-responsive LnCaP cells. To examine the possible effect of calcitonin on growth of invasive prostate cancer cells, we tested its effects on proliferation of PC-3M cells. Calcitonin stimulated DNA synthesis of PC-3M cells in a dose-dependent fashion, and also stimulated adenylyl cyclase and protein kinase C activities. To further delineate the role of these signaling cascades in proliferation of PC-3M prostate cancer cells, we selectively activated these pathways by transfecting cDNAs expressing constitutively active forms of either Gsalpha (Gsalpha-QL) or Gqalpha (Gqalpha-QL). cDNAs expressing wild-type forms of G-proteins (Gsalpha-WT and Gqalpha-WT) were used as vehicle controls. Gqalpha-QL transfectants exhibited growth inhibition and terminal differentiation. Those expressing Gsalpha-QL exhibited a dramatic increase in growth rate. Gsalpha-QL transfectants displayed an almost 3-fold increase in [3H]-thymidine incorporation and over a 4-fold increase in growth rate when compared with parental PC-3M cells or those expressing wild-type Gsalpha (Gsalpha-WT). The growth-promoting action of Gsalpha-QL could not be mimicked by either 8-bromo cAMP or forskolin. However, nifedipine, a calcium channel antagonist, potently and selectively inhibited DNA synthesis in Gsalpha-QL transfectants. These results suggest that the growth-promoting actions of Gsalpha on PC-3M cells may be mediated by nifedipine-sensitive proliferative events.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11149419     DOI: 10.1002/1097-0215(20010101)91:1<46::aid-ijc1008>3.0.co;2-0

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis.

Authors:  Girish V Shah; Anbalagan Muralidharan; Shibu Thomas; Mitan Gokulgandhi; Mudit Mudit; Mohammad Khanfar; Khalid El Sayed
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

2.  Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling.

Authors:  Shibu Thomas; Maurizio Chiriva-Internati; Girish V Shah
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 5.150

3.  Metafectene is superior to lipofectamine in the transfection of G(s) alpha prostate cancer cells.

Authors:  Kenneth A Iczkowski; A Levi Omara-Opyene; Roland Klösel
Journal:  Mol Biotechnol       Date:  2004-10       Impact factor: 2.695

4.  Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer.

Authors:  Girish V Shah; Anbalagan Muralidharan; Mitan Gokulgandhi; Kamal Soan; Shibu Thomas
Journal:  J Biol Chem       Date:  2008-11-09       Impact factor: 5.157

5.  MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells.

Authors:  Eric W Robbins; Emily A Travanty; Kui Yang; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2008-09-15       Impact factor: 4.430

Review 6.  Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.

Authors:  Harm Westdorp; Annette E Sköld; Berit A Snijer; Sebastian Franik; Sasja F Mulder; Pierre P Major; Ronan Foley; Winald R Gerritsen; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2014-05-06       Impact factor: 7.561

7.  Calcitonin Receptor-Zonula Occludens-1 Interaction Is Critical for Calcitonin-Stimulated Prostate Cancer Metastasis.

Authors:  Ahmed Aljameeli; Arvind Thakkar; Shibu Thomas; Vijaybasker Lakshmikanthan; Kenneth A Iczkowski; Girish V Shah
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.